Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

  • Technology appraisal guidance
  • TA870
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Invitation to participate

Draft guidance: TA505 ACD2

Draft guidance: TA505 ACD